8-K: USPH Reports Record Q2 Visits, Raises 2025 Guidance

U.S. Physical Therapy, Inc. reported strong second-quarter 2025 results with record patient visits and increased full-year Adjusted EBITDA guidance.

Summary

• Adjusted EBITDA for the second quarter of 2025 was $26.9 million, an increase of $4.7 million, or 21.4%, from $22.1 million in the second quarter of 2024, primarily driven by higher patient visits.
• Net income attributable to USPH shareholders was $12.4 million for the second quarter of 2025, compared to $7.5 million for the second quarter of 2024.
• Earnings per share was $0.58 for the second quarter of 2025, up from $0.47 for the second quarter of 2024.
• Total revenue from physical therapy operations for the second quarter of 2025 increased $24.8 million, or 17.3%, to $168.3 million.
• Net rate per patient visit for the second quarter of 2025 was $105.33, up from $105.05 for the second quarter of 2024, despite an approximate 2.9% Medicare rate reduction effective January 1, 2025.
• Total patient visits were 1,558,756 for the second quarter of 2025, a 16.7% increase from the second quarter of 2024, including 28,493 home-care visits.
• Average daily patient visits per clinic (excluding home-care visits) reached an all-time high of 32.7 for the second quarter of 2025, compared to 30.6 for the second quarter of 2024.
• Industrial injury prevention services (IIP) revenue was $29.1 million for the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024.
• The company added six clinics and closed four clinics in the second quarter of 2025, bringing its total owned and/or managed clinic count to 768 as of June 30, 2025, up from 722 as of June 30, 2024.
• A quarterly dividend of $0.45 per share was declared, payable on September 12, 2025, to shareholders of record on August 22, 2025.
• Management increased its guidance for Adjusted EBITDA for full-year 2025 to a range of $93.0 million to $97.0 million.
• A share repurchase program was approved, authorizing the repurchase of up to $25 million of common stock through December 31, 2026.

Sentiment

Score: 8

Explanation: The filing reports strong financial performance across key metrics, including record patient visits, significant revenue and profit growth, and increased full-year guidance. Strategic acquisitions and a new share repurchase program further enhance the positive outlook, despite some increases in operating costs and interest expense.

Positives

• Adjusted EBITDA increased significantly by 21.4% to $26.9 million for Q2 2025, driven by higher patient visits.
• Net income attributable to USPH shareholders grew substantially from $7.5 million to $12.4 million in Q2 2025.
• Earnings per share increased to $0.58 in Q2 2025 from $0.47 in Q2 2024.
• Total patient visits reached an all-time record of 1,558,756 in Q2 2025, a 16.7% increase year-over-year.
• Average daily patient visits per clinic hit an all-time high of 32.7 in Q2 2025.
• Net rate per patient visit increased to $105.33 in Q2 2025, demonstrating strength despite a 2.9% Medicare rate reduction.
• Industrial injury prevention services (IIP) revenue grew by 22.6% and IIP gross profit increased by 25.8% in Q2 2025.
• The company expanded its clinic network, with 768 owned/managed clinics as of June 30, 2025, a net addition of 51 clinics since Q2 2024.
• Strategic acquisitions of home-care and multi-clinic practices are contributing to revenue growth.
• Full-year 2025 Adjusted EBITDA guidance was raised to a range of $93.0 million to $97.0 million, reflecting management's confidence.
• A quarterly dividend of $0.45 per share was declared, indicating consistent shareholder returns.
• A share repurchase program of up to $25 million was approved, signaling commitment to enhancing shareholder value.

Negatives

• Corporate office costs increased to $17.5 million in Q2 2025 from $14.2 million in Q2 2024, partly due to acquisition integration and new financial/HR system implementation.
• Interest expense increased by $0.4 million to $2.4 million in Q2 2025 due to a higher average outstanding balance on the revolving credit facility.
• Interest income decreased significantly to less than $0.1 million in Q2 2025 from $1.1 million in Q2 2024, as cash was deployed for acquisitions.
• Cash and cash equivalents decreased to $34.1 million as of June 30, 2025, from $112.9 million as of June 30, 2024, primarily due to funding acquisitions.

Risks

• Changes in Medicare rules and guidelines and reimbursement or failure of clinics to maintain their Medicare certification and/or enrollment status.
• Revenue received from Medicare and Medicaid being subject to potential retroactive reduction.
• Changes in reimbursement rates or payment methods from third-party payors, including government agencies, and changes in deductibles and co-pays owed by patients.
• Private third-party payors for services may adopt payment policies that could limit future revenue and profitability.
• Compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply.
• Compliance with state laws and regulations relating to the corporate practice of medicine and fee splitting, and associated fines and penalties for failure to comply.
• Competitive, economic or reimbursement conditions in markets which may require reorganization or closure of certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets.
• The impact of future public health crises and epidemics/pandemics.
• Certain acquisition agreements contain put-rights related to a future purchase of significant equity interests in subsidiaries or in a separate company.
• The impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations.
• Debt and financial obligations could adversely affect financial condition, ability to obtain future financing and ability to operate the business.
• Changes as the result of government enacted national healthcare reform.
• The ability to control variable interest entities for which there is no direct ownership.
• Business and regulatory conditions including federal and state regulations.
• Governmental and other third-party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs.
• Contingent consideration provisions in certain acquisition agreements, the value of which may impact future financial results.
• Legal actions, which could subject the company to increased operating costs and uninsured liabilities.
• General economic conditions, including but not limited to inflationary and recessionary periods.
• Actual or perceived events involving banking volatility or limited liability, defaults or other adverse developments that affect the U.S or the international financial systems, may result in market-wide liquidity problems.
• Business depends on hiring, training, and retaining qualified employees, including physical therapists.
• Competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements.
• Ability to identify and complete acquisitions, and the successful integration of the operations of the acquired businesses.
• Impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest.
• Maintaining information technology systems with adequate safeguards to protect against cyber-attacks.
• A security breach of IT systems may subject the company to potential legal action and reputational harm and may result in a violation of HIPAA.
• Maintaining clients for which management, industrial injury prevention related services, and other services are performed, as a breach or termination of those contractual arrangements could cause operating results to be less than expected.
• Maintaining adequate internal controls.
• Maintaining necessary insurance coverage.
• Availability, terms, and use of capital.
• Weather and other seasonal factors.

Future Outlook

Management raised its Adjusted EBITDA guidance for full-year 2025 to a range of $93.0 million to $97.0 million, based on strong year-to-date performance and confidence in delivering solid results for shareholders in the second half of 2025. Implementation costs for the new financial and human resources system are expected to continue through the end of 2026.

Management Comments

• Volumes in our physical therapy business remain at record levels while we execute our plan for cost rationalization and improved efficiencies.
• Our injury prevention business continues a strong growth path, both organically and through carefully added acquisitions, which have broadened our service offerings and increased our exposure to new industry verticals.
• As a result of our efforts and expected progress we have updated our earnings guidance for the year.

Industry Context

The company operates in the growing outpatient physical therapy and industrial injury prevention sectors, which benefit from an aging population, increased focus on preventative care, and workplace safety. Its strategy of acquiring multi-clinic practices and expanding into home-care services aligns with broader healthcare trends towards diversified service delivery and patient convenience. The ability to increase net rates per patient visit despite Medicare rate reductions suggests effective contract negotiations and a favorable payor mix, positioning the company well within a competitive and evolving reimbursement landscape.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing for direct comparison to industry standards.

Stakeholder Impact

• Shareholders are positively impacted by strong financial performance, increased earnings per share, raised guidance, a declared dividend, and the approval of a share repurchase program.
• Employees may benefit from potential growth and stability due to clinic expansion and strong business performance.
• Customers (patients) gain increased access to services through clinic expansion and acquisitions, including new home-care options.
• Creditors face increased outstanding borrowings on the revolving credit facility, but the company's strong financial performance suggests a solid ability to manage its obligations.

Next Steps

• Filing of Quarterly Report on Form 10-Q with the Securities and Exchange Commission on August 8, 2025.
• Management will host a conference call on August 7, 2025, to discuss financial results.
• Continued execution of the strategy to acquire multi-clinic outpatient physical therapy practices and home-care physical and speech therapy practices.
• Development of outpatient physical therapy clinics as satellites in existing partnerships.
• Continued acquisition of companies that provide industrial injury prevention services.
• Share repurchases under the approved program through December 31, 2026.
• Implementation costs associated with the new financial and human resources system are expected to continue through the end of 2026.

Key Dates

Recommendation

The company demonstrates robust growth across its core physical therapy and industrial injury prevention segments, evidenced by record patient visits, significant revenue increases, and strong Adjusted EBITDA growth. The ability to increase net rates despite Medicare reductions highlights operational efficiency and strong payor relationships. Management's decision to raise full-year guidance and initiate a share repurchase program, alongside a consistent dividend, signals confidence in future performance and commitment to shareholder returns. While cash reserves have been deployed for strategic acquisitions, the overall financial health and growth trajectory make this an attractive investment.

Keywords

Physical therapy, Outpatient clinics, Industrial injury prevention, Healthcare services, USPH, Financial results, Q2 2025, Earnings, EBITDA, Patient visits, Clinic expansion, Dividends, Share repurchase